Navigation Links
BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis
Date:7/3/2009

TURKU, Finland, July 3 /PRNewswire/ -- BioCis Pharma Ltd., a privately held drug development company with its headquarters in Turku, Finland, announced positive results from its Phase IIa clinical trial of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. This double-blind, placebo-controlled study, conducted in Finland, included 13 patients with mild to moderate atopic dermatitis who applied the ProtoCure emulsion cream to the affected skin areas twice daily for up to four weeks. The objectives were to evaluate the tolerability, pharmacokinetics, and efficacy of the topical treatment.

Study results showed excellent safety profile, and no serious adverse events were reported during the study. No patient dropped out due to adverse side effects of the treatment. Pharmacokinetic analyses showed no systemic exposure to the active ingredient of the product. Efficacy was assessed by performing instrumental measurements of skin lesion redness (erythema) and skin barrier function by trans-epidermal water loss (TEWL) during the 28-day period. Physician assessments, such as Eczema Area and Severity Index (EASI) were also evaluated. ProtoCure emulsion cream was superior to placebo in decreasing skin redness and improving skin barrier function. Statistically significant improvement was observed as early as day 10 after begining treatment. There was also a significant improvement in EASI score over the whole treatment period for ProtoCure emulsion cream as a sign of positive treatment effect. The EASI score difference did not reach statistical significance when compared to placebo, mainly due to the small number of patients studied.

"We are very pleased with the promising results of this study," says Lasse Leino, CEO of BioCis Pharma. "Skin barrier dysfunction is now recognized as a hallmark feature of atopic dermatitis. Any drug showing capacity for restoring this disturbance has significant potential in atopic dermatitis therapy. Based on our results, ProtoCure(TM) emulsion cream holds great promises in the treatment of inflammatory skin disorders."

Atopic dermatitis is a chronic inflammatory disease of the skin with an onset typically already in infancy. It affects up to 20 per cent of the general population in the Western countries, and the prevalence rate is rising. Atopic dermatitis may significantly impair the quality of life of those affected. Existing treatments often have undesirable side effects and do not always meet the needs of patients.

BioCis Pharma Ltd. is a Karolinska Development portfolio company.

BioCis Pharma Ltd is an innovative drug development company developing drug therapies based on a novel, patented therapeutic principles that target unmet medical needs in substantial therapeutic markets including inflammation, allergy, and cancer. The company's main investors are Karolinska Development AB (publ.), Finnish Industry Investment Ltd., and Etra Invest Ltd.

http://www.biocis.com

Contacts: Dr. Lasse Leino, CEO, BioCis Pharma Ltd., mobile phone +358-40-849-4694, lasse.leino@biocis.com


'/>"/>
SOURCE BioCis Pharma Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
2. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
3. King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
4. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
5. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
6. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
7. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
8. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
9. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
10. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
11. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 /PRNewswire/ - StarFish Medical, ... development firm, announced today that it has merged with ... medical device industrial design and productization organization.  The resulting ... North America with easier east coast ... the design, engineering, regulatory, and manufacturing process. ...
(Date:3/28/2017)... BOSTON , March 28, 2017 /PRNewswire/ ... today announced a partnership with premium news ... allows pharmaceutical companies to extract key insights from ... text mining technology. The Linguamatics I2E ... top 20 global pharmaceutical companies. The Linguamatics-Dow Jones ...
(Date:3/28/2017)... , March 28, 2017 Emosis SAS, ... new business entity, Emosis Ltd, headquartered in Tel Aviv ... novel assays complementing the mother company existing technology platform and test ... sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. Emosis ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of ... Julie Taffet Moelis, W’81, have made a $10 million gift to establish the ... that will provide a pathway to a Wharton MBA for highly-qualified Penn undergraduates whose ...
(Date:3/29/2017)... ... March 29, 2017 , ... VisualSP has helped over 1.5 ... the only option for on-premises installation of its Help System for SharePoint was at ... the system into the entire tenant. , The company recently released a modified ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, ... public to take the Diabetes Risk Test to find out if they are at ... World Airports will light up the evening sky by programming the LAX pylons the ...
(Date:3/28/2017)... NEW YORK, NEW YORK (PRWEB) , ... March ... ... their breakthrough development, NTX Technology™, is the first technology to directly address the ... World Health Organization. NTX Technology™ is a patented compound of FDA and TTB ...
(Date:3/28/2017)... ... 2017 , ... Resoundant, Inc., the developer of Magnetic ... annual customer education symposium, a world-class learning conference that offers educational content designed ... 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations for ...
Breaking Medicine News(10 mins):